Summary Text

SUMMARY: First diagnosed with myeloma October 2011. Recruited onto clinical trial Myeloma X11 (Lenalidomide) at Bristol Oncology and Haematology Centre. First High Dose Therapy and Stem Cell Transplant (HDT&SCT) in July 2012. On maintenance until June 2017. June 2018 recruited onto Myeloma XII trial (Ixazomib). December 2018 Second HDT&SCT. On maintenance until February 2020. August 2020 Commenced treatment involving Daratumumab. April 2021 relapsed. June 2021 recruited onto Cartitude 4 clinical trial and infused with CAR-T cells in October 2021. My own immune system is now fighting the cancer . I am exceedingly fortunate.


Sunday, 2 May 2021

Relapse

It's still spring !


During my last post I reported that, because of my platelet count had improved and that I was responding to treatment.  I also needed a blood transfusion in order to improve my haemaglobin.  All this was sufficiently positive that I decided to return to my volunteering role.  The last few days have, however, been truly dramatic. 

 

First the good news: Yesterday I received my second Covid jab.  The team at my centre (the former RAF Locking) are so very friendly and efficient.  I can only thank them so very much.  As happened with my first jab, the second has now appeared on my health records.

 

At my routine consultant’s telephone call it became apparent that although my platelet count had continued to improve, my paraprotein count was also rising and thus indicating that the myeloma is relapsing.  My consultant then phoned me again to advise that my latest paraprotein result was in and showed further deterioration.  Accordingly I was now off the Daratumumab treatment and invited to a video conference to discuss the potential of being recruited onto a CAR-T Cell trial.

 

Life is about to get really quite complicated and unpredictable.  Firstly, my consultant wishes to assess some of my symptoms so tests and scans will be necessary.  The dates will be dependant on NHS facility availabilities.  When completed I will hopefully then be recommended for a trial  treatment called CAR-T Cell therapy.  There are two paths called Arms which are chosen by randomisation.  In Arm A, I would receive fairly standard therapy.  In Arm B, I would receive the CART Cell therapy. This requires taking some of my T Cells, which are part of the immune system, and sending them to the USA.  Once processed they are returned to me and will hopefully then attack my myeloma.  The overall process is complicated, lengthy and not without its risks.

 

If recommended for treatment I will then be subject to the following schedule:

 

-       Screening (28 days)

-       Apheresis (collection of T Cells taking just 1 day)

-       Bridging Therapy (minimum one cycle taking 28 days)

-       Conditioning (chemo in hospital taking 3 days)

-       CAR T Cell infusion (Probably over 1 day, in hospital)

-       Hospital monitoring (minimum 14 days)

-       Home monitoring thereafter

 

Apheresis to CAR-T Cell infusion is expected to take 5 to 6 weeks.  Time in hospital will be dependant on side effect – some of which can be severe but treatable.

 

In recognition of what my future now holds, and in particular its unpredictability, I have decided, and with sadness, to resign from volunteering.  This time I did not consider being placed on sabbatical to be appropriate.

 

Yesterday is the past, tomorrow is the future, but today is a gift

That is why it is called the present.

Bill Keane


Keep safe, keep well and KBO

Stephen